GEXVal Senior Director Speaks at University of Tokyo Hospital Drug Discovery Training Program

GEXVal Inc.
December 12, 2025

GEXVal Senior Director Delivers Lecture at University of Tokyo Hospital TR/Academia Drug Discovery Training Program 2025

GEXVal Inc. (President and CEO: Juran Kato, PhD; Location: Fujisawa, Kanagawa, Japan, hereinafter “GEXVal”) announces that Dr. Toshitake Kobayashi, Senior Director of Clinical Development, was invited to speak at the "TR・Academia Training Program 2025" hosted by The University of Tokyo Hospital, where he delivered a lecture titled "Manufacturing in Drug Discovery: The Art and Science."

The program aims to develop professionals who can bridge academic research, drug discovery, clinical trials, and market implementation, addressing critical challenges in Japanese healthcare including drug lag, drug loss, and declining domestic drug discovery capabilities.

In his lecture, Dr. Kobayashi presented a distinctive end-to-end perspective on drug manufacturing, systematically covering the progression from medicinal chemistry (structure optimization) through process chemistry (scalable synthesis) to CMC (regulatory manufacturing controls)—drawing from his extensive hands-on experience across all these disciplines.

The lecture was well-received by participants, who noted that "the perspective from someone with years of chemistry experience was refreshing and highly educational" and appreciated "the comprehensive coverage of the drug discovery process, which was valuable from a career perspective as well." Participant feedback showed strong satisfaction, with all respondents indicating they were satisfied and over 70% expressing high satisfaction with the content.

Dr. Juran Kato, President and CEO of GEXVal, also presented at the same program on November, speaking on "How to Deliver Medicines to Patients with Rare Diseases," demonstrating the company's comprehensive expertise spanning from drug discovery to development.

**Presentation Details**

[About GEXVal]
GEXVal strives to create and develop innovative pharmaceuticals for unmet medical needs, ensuring Treatment Reaches the Unreached with focus on rare diseases and underserved medical conditions. By leveraging our proprietary AI-powered pharmacoinformatics technology, we illuminate paths to breakthrough therapies, identifying hidden potential in drug candidates to deliver life-changing medicines that bring new hope to patients and their families.

For further information:
Head of Corporate Office
Atsushi Sugizaki
info@gexval.com